One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients

Journal of Neurology

Volumn 258, Issue 5, 2011, Pages 895-903

  Malucchi, Simona ^a   Gilli, Francesca ^a   Caldano, Marzia ^a   Sala, Arianna ^a   Capobianco, Marco ^a   Di Sapio, Alessia ^a   Granieri, Letizia ^a   Bertolotto, Antonio ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Binding antibodies (BAbs); Interferon beta; Multiple sclerosis; MxA; Neutralizing antibodies (NAbs)

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; ASSAY; BIOLOGICAL ACTIVITY; BLOOD EXAMINATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; DRUG TOLERANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GTP-BINDING PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 79960015067     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5844-5     Document Type: Article

References (40)

1. Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70(13 Pt 2):119-127
2. Gilli F, Marnetto F, Caldano M et al (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158:195-203 (Pubitemid 39626087)
3. Gilli F, Marnetto F, Caldano M et al (2006) Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 12:47-57 (Pubitemid 43169237)
4. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52:1239-1243 (Pubitemid 29177928)
5. Vallittu AM, Halminen M, Peltoniemi J, The Finnish Beta-Interferon Study Group et al (2002) Neutralizing antibodies reduce MxA protein induction in interferon beta-1a-treated MS patients. Neurology 58:1786-1790 (Pubitemid 34663579)
6. Vallittu AM, Salmi AA, Eralinna JP, Finnish Beta-Interferon Study Group (2006) MxA protein induction in MS patients treated with intramuscular IFNbeta-1a. Neurol Sci 26(6):438-443
7. Vallittu AM, Eralinna JP, llonen J, Salmi AA, Waris M (2008) MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. Acta Neurol Scand 118(1):12-17 (Pubitemid 351809324)
8. Pachner AR, Narayan K, Price N, Hurd M, Dail D (2003) MxA gene expression analysis as an interferon-β bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 7:17-25 (Pubitemid 37339029)
9. Pachner AR, Dail D, Pak E, Narayan K (2005) The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies. J Neuroimmunol 166:180-188 (Pubitemid 41078773)
10. Pachner AR, Narayan K, Pak E (2006) Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 66(3):444-446 (Pubitemid 43739958)
11. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R (2000) Interferon β neutralising antibodies in multiple sclerosis: neutralising activity and cross-reactivity with three different preparations. Immunopharmacology 48:95-100 (Pubitemid 30608666)
12. Bertolotto A, Gilli F, Sala A et al (2003) Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 60:634-639 (Pubitemid 36246082)
13. Gilli F, Bertolotto A, Sala A et al (2004) Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 127(pt 2):259-268 (Pubitemid 38160311)
14. Sominanda A, Hillert J, Fogdell-Hahn A (2008) In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralizing antibodies is titre dependent. J Neurol Neurosurg Psychiatry 79(1):57-62
15. van der Voort L, Kok A, A. Visser, Oudejans C, Caldano M, Gilli F, Bertolotto A, Polman C, Killestein J (2009) Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler 15(2):212-218
16. Ravnborg M, Bendtzen K, Christensen O, Jensen P, Hesse D, Towey M, Sorensen P (2009) Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler 15(3):323-328
17. Malucchi S, Sala A, Gilli F et al (2004) Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62:2031-2037 (Pubitemid 38738217)
18. Kawade Y (1986) Quantitation of neutralization of interferon by antibody. Methods Enzymol 119:558-573 (Pubitemid 16025159)
19. Kawade Y, Finter N, Grossberg SE (2003) Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods 278:127-144 (Pubitemid 37281197)
20. Grossberg SE, Kawade Y, Kohase M, Klein JP (2001) The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21:743-755 (Pubitemid 32955704)
21. Antonelli G, Bagnato F, Pozzilli C et al (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFNβ-1a. J Interferon Cytokine Res 18:345-350 (Pubitemid 28226180)
22. Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A (1999) ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β. J Immunol Methods 227:121-135 (Pubitemid 29408710)
23. Gilli F, Marnetto F, Stefanuto G et al (2004) Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol Diagn 8:185-194 (Pubitemid 40476074)
24. Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT (2001) Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256:141-152 (Pubitemid 32769923)
25. Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano M, di Sapio A, Capobianco M, Gilli F (2004) Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. JNNP 75:1294-1299 (Pubitemid 39141336)
26. McKay F, Schibeci S, Heard R, Stewart G, Booth D (2006) Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple slcerosis patients: a comparison of three methods in a large Australasian cohort. J Immunol Methods 310(1-2):20-29 (Pubitemid 43375972)
27. Lesko LJ, Atkinson AJ Jr (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347-366 (Pubitemid 32390116)
28. US Food and Drug Administration: Guidance for Industry - pharmacogenomic data submissions (2009) Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/ 2003d-0497-gdl0002.pdf. Accessed 29 July 2009
29. Bielekova B, Martin R (2004) Development of biomarkers in multiple sclerosis. Brain 127:1467-1478
30. de Veer MJ, Holko M, Frevel M, Walker E, der S, Paranjape JM, Silverman RH, Williams BR (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69(6):912-920 (Pubitemid 32577892)
31. von Wussow P, Jakschies D, Hochkeppel HK, Fibich C, Penner L, Deicher H (1990) The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 20(9):2015-2019 (Pubitemid 20355624)
32. Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, di sapio A, Capobianco M, Sala A, Malucchi S, Kappos L, Lindberg R, Bertolotto A (2007) Anti-interferon-β neutralizing activityisnot entirely mediated by antibodies. J Neuroimmunol 192(1-2):198-205 (Pubitemid 350213126)
33. Dupont SA, Goelz S, Goyal J, Green M (2002) Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res 22(4):491-501 (Pubitemid 34579552)
34. François C, Bernard I, Castelain S, Charleston B, Fray MD, Capiod JC, Duverlie G (2005) Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation. Antimicrob Agents Chemother 49(9):3770-3775 (Pubitemid 41233030)
35. Twork S, Nippert I, Scherer P, Haas J, Kugler J (2007) Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin 23(6):1209-1215 (Pubitemid 46998430)
36. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP (2008) Long-term adherence to interferon beta therapy in relapsingremitting multiple sclerosis. Eur Neurol 59(3-4):131-135 (Pubitemid 351301255)
37. Santos R, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Zivadinov R, Justinger T, Munschauer F 3rd, Ramanathan M (2006) Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 176(1-2):125-133 (Pubitemid 44080329)
38. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group (2003) Danish Interferon-beta Project. Antibodies to IFN-beta: the Danish National IFN-beta project. Neurology 61(9 Suppl 5):S27-S28 (Pubitemid 37386117)
39. Gneiss C, Reindl M, Lutterotti A, Ehling R, Egg R, Khalil M, Berger T, Deisenhammer F (2004) Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 10(5):507-510 (Pubitemid 39207222)
40. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C, Antonelli G (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFNbeta for 6 years. J Neurol Sci 215(1-2):3-8 (Pubitemid 37272189)